ABT-888 (Veliparib): Potent PARP Inhibitor for DNA Repair Inhibition

Executive Summary: ABT-888 (Veliparib) is a highly selective inhibitor of poly (ADP-ribose) polymerase 1 and 2 (PARP1/2), exhibiting inhibition constants (Ki) of 5.2 nM (PARP1) and 2.9 nM (PARP2) under standard biochemical assays at 25°C [APExBIO]. The compound impairs single-strand DNA break repair, sensitizing tumor cells to cytotoxic agents, especially in microsatellite instability (MSI) or DNA repair-deficient models (Pettenger-Willey et al., 2025). ABT-888 displays in vivo efficacy and synergy with SN38 and oxaliplatin in colorectal cancer xenografts. Supplied by APExBIO, the research-grade product (SKU A3002) exceeds 99.5% purity as verified by HPLC and NMR. The compound is insoluble in water but dissolves in DMSO (≥6.11 mg/mL) or ethanol (≥10.6 mg/mL) with ultrasonic assistance.

Biological Rationale

Poly (ADP-ribose) polymerases (PARPs) are enzymes essential for the detection and repair of single-strand DNA breaks. PARP1 and PARP2 facilitate recruitment of DNA repair machinery via poly-ADP ribosylation. Inhibition of PARP activity leads to persistence of DNA lesions, which can result in double-strand breaks upon replication. Tumor cells with defects in homologous recombination repair (HRR), such as those with BRCA, MRE11, or RAD50 mutations, are particularly vulnerable to PARP inhibition [Interlink: expands on mechanistic detail]. ABT-888 (Veliparib) exploits this synthetic lethality, enhancing the cytotoxic effect of DNA-damaging agents.

Mechanism of Action of ABT-888 (Veliparib)

ABT-888 is a competitive, NAD⁺-dependent inhibitor of PARP1 and PARP2, binding to the catalytic domain and blocking ADP-ribosylation activity. This action prevents repair of single-strand DNA lesions, leading to accumulation of DNA damage. The impaired DNA damage response (DDR) is especially pronounced in MSI-high or HRR-deficient tumor models. When used in combination with chemotherapeutics (e.g., SN38, oxaliplatin) or radiation, ABT-888 heightens cellular sensitivity to these treatments. This effect has been quantified in multiple preclinical models, including colorectal cancer xenografts and MSI cell lines [Interlink: compares protocol scenarios].

Evidence & Benchmarks

• ABT-888 inhibits PARP1 and PARP2 with Ki values of 5.2 nM and 2.9 nM, respectively, as determined by enzymatic assays at 25°C, pH 7.4 (APExBIO, product page).
• In DNA repair-deficient or MSI tumor models, ABT-888 synergistically enhances the efficacy of SN38 and oxaliplatin, delaying tumor growth in murine xenograft studies (see related article and benchmark data).
• APExBIO’s ABT-888 (SKU A3002) is supplied at >99.5% purity, verified by HPLC and NMR under GMP-like conditions (APExBIO).
• In a genome-wide CRISPR/Cas9 screen, PARP inhibition did not significantly increase calicheamicin cytotoxicity in acute leukemia cell lines, indicating specificity to DNA repair-deficient contexts (Pettenger-Willey et al., 2025).
• ABT-888 is insoluble in water at 25°C but dissolves in DMSO (≥6.11 mg/mL) or ethanol (≥10.6 mg/mL) with ultrasonic assistance; solutions are stable at -20°C for short-term use (APExBIO).

Applications, Limits & Misconceptions

ABT-888 is primarily utilized in preclinical research as a PARP inhibitor for cancer chemotherapy sensitization and DNA repair inhibition studies. Typical applications include:

• Sensitization of colorectal, breast, and ovarian cancer models to DNA-damaging agents.
• Functional studies in MSI tumor models with known DNA repair gene mutations (e.g., MRE11, RAD50).
• Assays exploring the caspase signaling pathway, DNA damage response (DDR), and PARP-mediated repair mechanisms [Interlink: provides strategic guidance].

Common Pitfalls or Misconceptions

• Not effective in all tumor types: ABT-888 has limited efficacy in cells with intact homologous recombination repair (HRR) or wild-type TP53, as confirmed by CRISPR/Cas9 studies (DOI).
• Not a diagnostic or therapeutic agent: ABT-888 from APExBIO is for research use only, not for clinical or diagnostic purposes (APExBIO).
• Solubility limitations: Insoluble in water; improper solvent selection or lack of ultrasonic treatment may limit assay performance.
• Not universally synergistic: No significant enhancement of calicheamicin cytotoxicity in acute leukemia models; synergy is context-dependent (DOI).
• Long-term storage instability: Stock solutions in DMSO or ethanol are not recommended for long-term storage due to potential compound degradation.

Workflow Integration & Parameters

For in vitro use, ABT-888 is typically prepared as a >10 mM stock in DMSO with warming and ultrasonic assistance. Working concentrations in cell-based assays range from 0.01 to 10 μM, depending on experimental design. Solutions should be freshly prepared and stored at -20°C. The solid compound should be stored at -20°C, protected from light and moisture. Integration into DNA damage assays or cell viability workflows should consider compound solubility and the genetic background of the cell lines used. For detailed protocol optimization and troubleshooting, see this article, which addresses workflow challenges specific to ABT-888.

Conclusion & Outlook

ABT-888 (Veliparib) remains a gold-standard tool for studying PARP-mediated DNA repair inhibition and chemotherapy sensitization in research models. Its selectivity, potency, and robust validation in MSI and DNA repair-deficient tumors support its continued role in preclinical oncology workflows. While its synergy is context-dependent, the compound is indispensable for mechanistic studies of the DNA damage response pathway. For product specifications, protocols, or to purchase, visit the ABT-888 (Veliparib) product page offered by APExBIO.